Dengue Virus Cross-Reactive Hemagglutination Inhibition Antibody Responses in Patients with Primary Dengue Virus Infection

DOI Web Site Web Site
  • Anantapreecha Surapee
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • A-nuegoonpipat Atchareeya
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • Prakrong Songthum
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • Chanama Sumalee
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • Sa-ngasang Areerat
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • Sawanpanyalert Pathom
    National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand
  • Kurane Ichiro
    Department of Virology I, National Institute of Infectious Diseases, Japan

この論文をさがす

抄録

<p>Acute and convalescent plasma samples were obtained from 101 confirmed primary dengue cases: 48 cases infected with dengue virus type 1, 10 cases with type 2, 42 cases with type 3 and one case with type 4. The hemagglutination inhibition (HI) titers of individual samples were at levels similar to each of the 4 dengue viruses at both the acute and convalescent stages, irrespective of the dengue virus that infected the patients. The results indicate that HI antibodies to dengue viruses are cross-reactive. When an HI test is used as a diagnostic test for dengue virus infection, the cross-reactive nature needs to be considered when interpreting the results.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ